Led by $880.85m asset transaction with Novasep Holding, Europe’s medical devices industry saw a rise of 0.55% in cross border deal activity during Q1 2021, when compared to the last four-quarter average, according to GlobalData’s deals database.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all
  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

 

A total of 46 cross border deals worth $2.73bn were announced for the region during Q1 2021, against the last four-quarter average of 45.75 deals.

Of all the deal types, M&A saw most activity in Q1 2021 with 26 deals, representing a 56.5% share for the region.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In second place was venture financing with 16 deals, followed by private equity deals with four transactions, respectively capturing a 34.8% and 8.7% share of the overall cross border deal activity for the quarter.

In terms of value of cross border deals, M&A was the leading category in Europe’s medical devices industry with $2.37bn, while private equity and venture financing deals totalled $212.52m and $148.41m, respectively.

Europe medical devices industry cross border deals in Q1 2021: Top deals

The top five medical devices cross border deals accounted for a 78.7% share of the overall value during Q1 2021.

The combined value of the top five cross border deals stood at $2.15bn, against the overall value of $2.73bn recorded for the quarter.

The top five medical devices industry cross border deals of Q1 2021 tracked by GlobalData were:

1) Thermo Fisher Scientific’s $880.85m asset transaction with Novasep Holding

2) The $591m acquisition of Oxford Immunotec by PerkinElmer

3) Savaria’s $409.7m acquisition of Handicare Group

4) The $159m acquisition deal with Diagenode by Hologic

5) Sino Biopharmaceutical’s acquisition of Softhale for $110m.